Pharmacodynamic and antitumor activity of BI 836880, a dual vascular endothelial growth factor and angiopoietin 2 inhibitor, alone and combined with programmed …
I Hofmann, A Baum, MH Hofmann, F Trapani… - The Journal of …, 2023 - Elsevier
Vascular endothelial growth factor (VEGF) and angiopoietin (ANG)-2 have complementary
roles in angiogenesis and promote an immunosuppressive tumor microenvironment. It is
anticipated that the combination of VEGF and ANG2 blockade could provide superior activity
to the blockade of either pathway alone and that the addition of VEGF/ANG2 inhibition to an
anti–programmed cell death protein-1 (PD-1) antibody could change the tumor
microenvironment to support T-cell–mediated tumor cytotoxicity. Here, we describe the …
roles in angiogenesis and promote an immunosuppressive tumor microenvironment. It is
anticipated that the combination of VEGF and ANG2 blockade could provide superior activity
to the blockade of either pathway alone and that the addition of VEGF/ANG2 inhibition to an
anti–programmed cell death protein-1 (PD-1) antibody could change the tumor
microenvironment to support T-cell–mediated tumor cytotoxicity. Here, we describe the …
Pharmacodynamic and antitumor activity of BI 836880, a dual VEGF and angiopoietin 2 inhibitor, alone and combined with programmed cell death protein-1 inhibition
I Hofmann, A Baum, MH Hofmann… - J. Pharmacol. Exp …, 2022 - jpet.aspetjournals.org
Supplementary Table S3. Least squares means (predicted) and treatment ratio for tumor
volume (mm3): results from a repeated measurement mixed model comparing treatment with
anti-PD-1 plus anti-VEGFR2 with anti-PD-1 plus anti-VEGFR2 plus anti-ANG2. Female
C57BL/6NTac mice bearing LL/2 lung cancer tumors were treated with RMP 1-14 (anti-PD-1
antibody; 10 mg/kg twice-weekly intraperitoneally), vatalanib (anti-VEGFR2 small molecule
inhibitor; 100 mg/kg; once-daily by oral gavage), BI 836880 (used as anti-mouse ANG2 …
volume (mm3): results from a repeated measurement mixed model comparing treatment with
anti-PD-1 plus anti-VEGFR2 with anti-PD-1 plus anti-VEGFR2 plus anti-ANG2. Female
C57BL/6NTac mice bearing LL/2 lung cancer tumors were treated with RMP 1-14 (anti-PD-1
antibody; 10 mg/kg twice-weekly intraperitoneally), vatalanib (anti-VEGFR2 small molecule
inhibitor; 100 mg/kg; once-daily by oral gavage), BI 836880 (used as anti-mouse ANG2 …